CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers explore a promising alternative using dbDNA, an innovative linear DNA vector that could dramatically reduce manufacturing costs while eliminating safety concerns associated with traditional plasmid-based methods.

Download the full article to discover how scientists overcame initial technical challenges to successfully produce functional CAR19 T cells using this novel approach.